Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient
| Autor: | Evelyne Kohli, Jérôme Berger, Gilles Collin, Nadhira Houhou-Fidouh, Yves Michiels |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Immunology
BNT162b2 vaccine ChAdOx1 nCoV-19 vaccine SARS-CoV-2 antibody response teriflunomide Heterologous Case Report Viral vector chemistry.chemical_compound Immune system Drug Discovery Teriflunomide medicine Pharmacology (medical) Neutralizing antibody Pharmacology biology business.industry Multiple sclerosis medicine.disease Vaccination Regimen Infectious Diseases chemistry biology.protein Medicine business |
| Zdroj: | Vaccines, vol. 9, no. 10, pp. 1140 Vaccines Vaccines, Vol 9, Iss 1140, p 1140 (2021) |
| ISSN: | 2076-393X |
| Popis: | Patients with multiple sclerosis (MS) are treated with drugs that may impact immune responses to SARS-CoV-2 vaccination. Evaluation of “prime-boost” (heterologous) vaccination regimens including a first administration of a viral vector-based vaccine and a second one of an mRNA-based vaccine in such patients has not yet been completed. Here, we present the anti-spike protein S humoral response, including the neutralizing antibody response, in a 54-year-old MS patient who had been treated with teriflunomide for the past 2 years and who received a heterologous ChAdOx1 nCoV-19/ BNT162b2 vaccination regimen. The results showed a very strong anti-S IgG response and a good neutralizing antibody response. These results show that teriflunomide did not prevent the development of a satisfactory humoral response in this MS patient after vaccination with a ChAdOx1 nCoV-19/ BNT162b2 prime-boost protocol. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|